This invention is to provide a means capable of obtaining excellent cell proliferation activity without depending on a thickness of a coating layer in a technique of coating a cell culture substrate (cell culture vessel) using a polymer. Provided is a cell culture substrate comprising a coating layer on at least one surface of a polymer substrate, wherein the coating layer includes a copolymer comprising more than 40% by mole and less than 100% by mole of a structural unit (1) derived from carboxyalkyl (meth)acrylate represented by Formula (1) and more than 0% by mole and less than 60% by mole of a structural unit (2) derived from ethylenically unsaturated monomer having a hydroxyl group (the total of the structural unit (1) and the structural unit (2) is 100% by mole).

The present invention relates to a method for preparing oncolytic virus-containing mesenchymal stem cells having improved cell viability, a method for storing the oncolytic virus-containing stem cells produced by the method, and a cell therapeutic agent for cancer treatment containing the oncolytic virus-containing stem cells produced by the method. More particularly, an oncolytic virus is introduced into mesenchymal stem cells, followed by treatment with aspirin, so that the infection efficiency of the oncolytic virus may be increased, the replication time of the virus may be prolonged, and lysis of the stem cells by the virus may be prevented, thereby improving the viability and survival period of the stem cells and preparing anticancer stem cells having excellent activity. The anticancer stem cell therapeutic agent produced in this way is maintained at high viability during cold storage due to aspirin treatment, and thus is very useful medically and industrially.

The present invention relates to a method for preparation of mesenchymal stem cells from human pluripotent stem cells and, more particularly, to a method for preparation of mesenchymal stem cells, wherein mesenchymal stem cells differentiated from embryoid bodies of a certain size in a xeno-free and serum-free environment are prepared, whereby the mesenchymal stem cells exhibit increased safety and maintain their own characteristics for a long period of time. A method for preparation of mesenchymal stem cells from human pluripotent stem cells according to the present invention employs a feeder cell-free, xeno-free, and serum-free culture environment to solve the problem of contamination with a foreign animal-derived material and allow the preparation of highly safe mesenchymal stem cells. In addition, the method utilizes spheroidal embryoid bodies to form mature embryoid bodies uniform in shape and size, thereby improving the differentiation efficiency to mesenchymal stem cells and exhibiting an exceptional effect of stably maintaining mesenchymal stem cell characteristics even after a long-term subculture, such as 20 or more passages, through which human pluripotent stem cell-derived mesenchymal stem cells can be prepared in a large amount. Therefore, the invention is advantageous for commercializing cell therapeutic agents superb in safety and efficiency.

Mesenchymal stem cells (MSCs) or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used in the treatment of chronic gingivostomatitis (CGS) in subjects, preferably in felines and canines. In a second aspect, MSCs or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used as an immunomodulating agent during the acute and/or the chronic phase of the CGS inflammatory reaction in subjects, preferably in felines and canines diagnosed with or suffering from chronic gingivostomatitis. In a last aspect, a pharmaceutical composition can comprise peripheral blood-derived MSCs.

Anti-aging cosmetic compositions prepared from conditioned medium of adipose-derived stem cells are provided. The cosmetic compositions are preferably ready-to-mix compositions, comprising two separate components: a protein component in a dried form that serves as the cosmetically active ingredient of the product, comprising a protein fraction purified from an adipose-derived stem cell conditioned medium; and a reconstitution component, for reconstituting the lyophilized protein component just before application to the skin.

Accordingly. the present disclosure provides a population of genetically engineered mesenchymal stem cells (MSCs), comprising an expression vector comprising an Akt or HGF gene and a PD-L1 gene. Also provided is a method for synergistically increasing survival status and immunomodulatory ability of an MSC or enhancing proliferation of an MSC, comprising transfecting an MSC with an Akt or HGF gene and a PD-L1 gene and a method for preventing, ameliorating and/or treating an ischemia condition, enhancing neuroregeneration or reducing neuronal death, comprising administering an effective amount of a population of genetically engineered MSCs of the present disclosure to a subject in need thereof.

The present disclosure relates to improved methods serum free stem cell culture, particularly 3D culture in bioreactors as well as cell culture medium and compositions for use in the same. Such methods may be particularly suitable for large scale cell manufacture.

Provided are methods of making and delivering vaccine compositions using an enucleated cell-based platform. Methods of clearing pathogenic infections in a subject using the enucleated cell-based platform is also provided. Such enucleated cell-based platform reduces the vaccine development timeline as compared with conventional biological vaccines, and improves vaccine efficacy.

Disclosed are novel cellular populations generated by explosion of monocytic cells to conditioned media of regenerative cells. In one embodiment said regenerative cells are umbilical cord endothelial cells and said cells are pre-activated to possess enhance ability to reprogram said monocytic lineage cells. In one embodiment monocyte lineage cells are collected from leukopaks by plastic adherence and subsequently cultured in a manner to generate cells similar to M2 cells. In one embodiment said monocytic cells are cultured in a manner to generate myeloid derived suppressor cells. In one embodiment cells are generated to reducing inflammatory conditions. In another embodiment cells are generated for treatment of degenerative conditions. In another embodiment cells are generated for treatment of fibrosis.

Provided herein are CRIS-PR/Cas9 complexes and methods of using same.